ArticleBritish journal of cancer2018
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Marzia Del Re et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this papercites it